Disease-free Survival in Locally Advanced Breast Cancer According to Pathological Response to Neoadjuvant Treatment
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 José Luis Reyes Cáceres, Valeria Bastidas López
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
DOI:
https://doi.org/10.33821/806Keywords:
breast cancer, neoadjuvant chemotherapy, pathologic complete response, disease-free survival, immunohistochemistryAbstract
Introduction: Neoadjuvant chemotherapy is the standard treatment for locally advanced breast cancer, as it increases rates of breast-conserving surgery and improves disease-free survival (DFS) in patients who achieve a complete pathological response. Methodology: A retrospective observational cohort study was conducted that included 31 patients with locally advanced breast cancer treated with neoadjuvant chemotherapy at the Solón Espinosa Ayala Oncology Hospital (SOLCA-Quito) between 2010 and 2014. Data were obtained from the Hospital Tumor Registry. The 5-year SLE was estimated using the Kaplan-Meier method, and prognostic factors were analyzed using logistic regression. Results: The mean age was 52.5 years. 93.5% presented invasive ductal carcinoma, with 48.5% showing moderate differentiation. The TAC regimen (docetaxel, doxorubicin, and cyclophosphamide) was administered to 96.8% of patients. Complete pathological response (Miller and Payne grade 5) was observed in 12.9%, while the most frequent partial response was grade 3 (48.4%). The 5-year SLE was 64.4%. A Ki-67 proliferation index greater than 14% was found to be associated with a lower SLE (OR: 0.067; 95% CI: 0.05-0.93; p<0.05). Conclusions: The 5-year SLE rate in this cohort was comparable to that reported in the literature. However, the limited sample size restricts the generalizability of- the results, so studies with a larger number of patients are needed to confirm these findings.
Downloads
References
Globocan. Latin America and the Caribbean [Internet]. 2020. Disponible en: https://gco.iarc.fr/today/data/factsheets/populations/904-latin-america-and-the-caribbean-fact-sheets.pdf
Cueva P, Tarupi W, Caballero H. Cancer incidence and mortality in Quito: information to monitor cancer control policies. Colombia Médica. 2022;53(1):e2024929. https://doi.org/10.25100/cm.v53i1.4929
Britt KL, Cuzick J, Phillips K-A. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020;20(8):417-36. https://doi.org/10.1038/s41568-020-0266-x
Wang M, Hou L, Chen M, Zhou Y, Liang Y, Wang S, et al. Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer. Sci Rep. 2017;7:44673. https://doi.org/10.1038/srep44673
Coughlin SS. Epidemiology of Breast Cancer in Women. Adv Exp Med Biol. 2019:1152:9-29. https://doi.org/10.1007/978-3-030-20301-6_2
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. https://doi.org/10.3322/caac.21583
Leon-Ferre RA, Hieken TJ, Boughey JC. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Ann Surg Oncol. 2021;28(4):2111-9. https://doi.org/10.1245/s10434-020-09480-9
D’Ottavio V, Díaz PJ, Cardozo V. Respuesta clínica y patológica tras el tratamiento sistémico neoadyuvante según los diferentes fenotipos moleculares y factores pronósticos en el cáncer de mama. Rev. argent. mastología. 2018;37(136):91–105. Disponible en: https://www.revistasamas.org.ar/revistas/2018_v37_n136/06.pdf
Lozano-Rodríguez CA, Rodríguez-Matías VA, Real-Cotto JJ, Jaramillo-Feijoo LE. Cáncer de mama y su respuesta al tratamiento neoadyuvante según subtipo molecular. J Health Med Sci. 2020;6(1):21–27. Disponible en: https://revistas.uta.cl/pdf/80/johamsc-61-21-27-2020-web03-04.pdf
Waldrep AR, Avery EJ, Rose FF Jr, Midathada MV, Tilford JA, Kolberg HC, et al. Breast cancer subtype influences the accuracy of predicting pathologic response by imaging and clinical breast exam after neoadjuvant chemotherapy. Anticancer Res. 2016;36(10):5389–5396. https://doi.org/10.21873/anticanres.11114. Disponible en: https://ar.iiarjournals.org/content/36/10/5389.full
Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23(3):505–523. https://doi.org/10.1016/j.soc.2014.03.009. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044615/
Semiglazov V. RECIST for response (clinical and imaging) in neoadjuvant clinical trials in operable breast cancer. JNCI Monogr. 2015;2015(51):21–23. https://doi.org/10.1093/jncimonographs/lgv021
Tan QX, Qin QH, Yang WP, Mo QG, Wei CY. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014;7(10):6862–6870. https://doi. org/10.1007/s13277-014-3055-9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230098/
Dhanushkodi M, Sridevi V, Shanta V, Rama R, Swaminathan R, Selvaluxmy G, et al. Locally advanced breast cancer (LABC): real-world outcome of patients from Cancer Institute, Chennai. JCO Glob Oncol. 2021;7:767–781. https://doi.org/10.1200/GO.20.00448. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457812/
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooledanalysis. Lancet. 2014;384(9938):164-72. https://doi.org/10.1016/s0140-6736(13)62422-8
Ospino R, Cendales R, Cifuentes J, Sánchez Z, Galvis J, Bobadilla I. Supervivencia en pacientes con cáncer de mama localmente avanzado tratadas con radioterapia posterior a mastectomía en el Instituto Nacional de Cancerología. Rev Colomb Cancerol. 2010;14(4):210–224. https://doi.org/10.1016/S0123-9015(10)70084-6. Disponible en: https://www.revistacancercol.org/index.php/cancer/article/view/438/292
Trabulsi NH, Shabkah AA, Ujaimi R, Iskanderani O, Kadi MS, Aljabri N, et al. Locally advanced breast cancer: treatment patterns and predictors of survival in a Saudi tertiary center. Cureus. 2021;13(6):e15896. https://doi. org/10.7759/cureus.15896. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269977/
Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020;26(12):2838-48. https://doi.org/10.1158/1078-0432.ccr-19-3492
Dhanushkodi M, Sridevi V, Shanta V, Rama R, Swaminathan R, Selvaluxmy G, et al. Locally advanced breast cancer (LABC): real-world outcome of patients from Cancer Institute, Chennai. JCO Glob Oncol. 2021;7:767–781. https://doi.org/10.1200/GO.20.00448. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457812/
Huang M, O’Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, et al. Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Res. 2020;80(24):5427-34. https://doi.org/10.1158/0008-5472.can-20-1792
Tan QX, Qin QH, Yang WP, Mo QG, Wei CY. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014;7(10):6862–6870. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230098/
Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvantchemotherapy in breast cancer; is it equally useful across tumor subtypes? Surgery. 2014;155(5):927-35. https://doi.org/10.1016/j.surg.2014.01.009
Shohdy KS, Almeldin DS, Fekry MA, Ismail MA, AboElmaaref NA, ElSadany EG, et al. Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: A single-institute experience. J Egypt Natl Canc Inst. 2021;33(1):39. https://doi.org/10.1186/s43046-021-00096-y
Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, et al. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(2):307-13. https://doi.org/10.1093/annonc/mdu528
